Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TIEG1 CRISPR/Cas9 KO Plasmid (h): sc-402480
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TIEG1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TIEG1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TIEG1 Antibody (95-D): sc-130408
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TIEG1 CRISPR/Cas9 KO Plasmid (h) | sc-402480 | 20 µg | $397.00 |
Overview
KLF10 encodes TIEG1 (TGF-β inducible early growth response protein 1), a Krüppel-like zinc-finger transcription factor that integrates transforming growth factor-β (TGF-β)/SMAD signaling with context-dependent control of cell cycle progression, differentiation, and apoptosis. TIEG1 regulates transcriptional programs involved in extracellular matrix remodeling and lineage commitment, and it can modulate cross-talk with MAPK and hormonal signaling pathways in epithelial, bone, and immune cell contexts. Altered KLF10/TIEG1 activity has been associated with dysregulated fibrotic responses, aberrant osteoblast function and bone remodeling, and changes in tumor suppressive transcriptional networks, making it relevant for mechanistic studies of proliferation control and tissue homeostasis. Its role as an early response factor positions it as a useful node for dissecting stimulus-dependent gene regulation and downstream pathway wiring.
TIEG1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KLF10 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KLF10 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KLF10 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TIEG1 protein expression.
This CRISPR knockout system enables efficient generation of KLF10-deficient cell models for investigation of TIEG1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting KLF10 exon(s) critical for TIEG1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple KLF10 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TIEG1 CRISPR/Cas9 KO Plasmid (h) and TIEG1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KLF10 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TIEG1 HDR Plasmid (h) and TIEG1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KLF10 homology arms to support homology-directed repair at defined KLF10 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.